COVAXIN shows interim clinical efficacy of 81 % in phase 3 results, says Bharat Biotech

India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.

Covaxin is India's totally indigenous COVID-19 vaccine developed



in collaboration with the Indian Council of Medical Research and National Institute of Virology.

The vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.

In Phase 1 and Phase 2 clinical trials, Covaxin demonstrated the ability to produce antibodies against Covid-19.